Thanks for the feedback. Just a couple of comments.MSCI EAFE is not an appropriate benchmark with which to compare MutualDiscovery, which is 50% U.S. The benchmark is 100% non-U.S. The Mutual Series funds as a whole are performing poorly relative to similar funds in the last year or so.Dr. Mobius' funds are performing poorly relative to other emerging markets funds, and the global equity funds are performing poorly relative to their peer group, as well, for the last couple of years. By the way, MSCI EAFE is an appropriate benchmark to compare the Templeton Foreign Fund. In the past, some of the relatively good perfomance of the Foreign Fund has been due to an unweighting of Japan relative to the index. To really evaluate Holowesko's stock picking during these periods, you would need to construct a different benchmark with a lower Japan weighting.Chinese Wall or no Chinese Wall, Templeton has lost a number of experienced portfolio analysts / managers since the acquistion by Franklin. Mike Price is opting out early from any active role at Mutual Series, and Franklin San Mateo has lost a number of analysts / portfolio persons in the last couple of years. Might this be contributing to the underperformance of Franklin Templeton Funds? This would be logical.Poor fund performance can't be sold, and there are the obvious asset retention problems. This will hurt future earnings.You seem like you might even work for FT, though not in portfolio management. What other problems do you see?
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar